The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Acer Therapeutics Inc | Common | 00444P108 | 17,442 | 565,579 | SH | SOLE | 565,579 | 0 | 0 | ||
Aclaris Therapeutics | Common | 00461U105 | 23,918 | 1,647,214 | SH | SOLE | 1,647,214 | 0 | 0 | ||
Agile Therapeutics, Inc. | Common | 00847L100 | 555 | 1,513,975 | SH | SOLE | 1,513,975 | 0 | 0 | ||
Akari Therapeutics Plc | ADR | 00972G108 | 885 | 345,850 | SH | SOLE | 345,850 | 0 | 0 | ||
Amyris, Inc. | Common | 03236M200 | 44,266 | 5,575,118 | SH | SOLE | 5,575,118 | 0 | 0 | ||
Apellis Pharmaceuticals, Inc. | Common | 03753U106 | 24,084 | 1,354,554 | SH | SOLE | 1,354,554 | 0 | 0 | ||
Arrowhead Pharmaceuticals In | Common | 04280A100 | 44,637 | 2,328,475 | SH | SOLE | 2,328,475 | 0 | 0 | ||
Arvinas Holding Co LLC | Common | 04335A105 | 5,061 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
Ascendis Pharma | ADR | 04351P101 | 153,542 | 2,166,832 | SH | SOLE | 2,166,832 | 0 | 0 | ||
Aurinia Pharmaceuticals Inc. | Common | 05156V102 | 8,056 | 1,213,290 | SH | SOLE | 1,213,290 | 0 | 0 | ||
Biohaven Pharmaceutical Holding Company Ltd | Common | G11196105 | 76,960 | 2,049,545 | SH | SOLE | 2,049,545 | 0 | 0 | ||
BioPharmX Corporation | Common | 09072X101 | 3,064 | 16,128,515 | SH | SOLE | 16,128,515 | 0 | 0 | ||
Codexis, Inc. | Common | 192005106 | 47,151 | 2,749,343 | SH | SOLE | 2,749,343 | 0 | 0 | ||
Crinetics Pharmaceuticals Inc | Common | 22663K107 | 108,646 | 3,792,169 | SH | SOLE | 3,792,169 | 0 | 0 | ||
Cymabay Therapeutics inc | Common | 23257D103 | 10,038 | 906,000 | SH | SOLE | 906,000 | 0 | 0 | ||
Deciphera Pharmaceuticals In | Common | 24344T101 | 8,234 | 212,648 | SH | SOLE | 212,648 | 0 | 0 | ||
Eiger BioPharmaceuticals | Common | 28249U105 | 21,495 | 1,791,257 | SH | SOLE | 1,791,257 | 0 | 0 | ||
Foamix Pharmaceuticals Ltd. | SHS | M46135105 | 2,450 | 427,500 | SH | SOLE | 427,500 | 0 | 0 | ||
Galmed Pharmaceuticals Ltd | SHS | M47238106 | 11,563 | 851,492 | SH | SOLE | 851,492 | 0 | 0 | ||
Genocea Biosciences Inc(NMS) | Common | 372427104 | 6,378 | 8,180,000 | SH | SOLE | 8,180,000 | 0 | 0 | ||
GTX Inc | Common | 40052B207 | 165 | 105,043 | SH | SOLE | 105,043 | 0 | 0 | ||
Homology Medicines, Inc. | Common | 438083107 | 26,512 | 1,159,742 | SH | SOLE | 1,159,742 | 0 | 0 | ||
Kadmon Holdings (KDMN) | Common | 48283N106 | 34,918 | 10,454,545 | SH | SOLE | 10,454,545 | 0 | 0 | ||
Kala Pharmaceuticals, Inc. | Common | 483119103 | 10,295 | 1,043,020 | SH | SOLE | 1,043,020 | 0 | 0 | ||
KalVista Pharmaceuticals, Inc. | Common | 483497103 | 30,051 | 1,359,149 | SH | SOLE | 1,359,149 | 0 | 0 | ||
Kiniksa Pharmaceuticals-A | Common | G5269C101 | 6,754 | 264,878 | SH | SOLE | 264,878 | 0 | 0 | ||
MEI Pharma Inc (NAS) | Common | 55279B202 | 24,904 | 5,778,106 | SH | SOLE | 5,778,106 | 0 | 0 | ||
Menlo Therapeutics | Common | 586858102 | 39,511 | 4,011,236 | SH | SOLE | 4,011,236 | 0 | 0 | ||
Nabriva Therapeutics Plc | SHS | G63637105 | 17,872 | 6,619,190 | SH | SOLE | 6,619,190 | 0 | 0 | ||
Obseva SA | Common | H5861P103 | 16,897 | 937,147 | SH | SOLE | 937,147 | 0 | 0 | ||
Selecta Biosciences, Inc. | Common | 816212104 | 11,837 | 761,253 | SH | SOLE | 761,253 | 0 | 0 | ||
Sierra Oncology, Inc | Common | 82640U107 | 4,145 | 2,438,270 | SH | SOLE | 2,438,270 | 0 | 0 | ||
Sinovac Biotech Ltd | SHS | P8696W104 | 44,958 | 5,900,000 | SH | SOLE | 5,900,000 | 0 | 0 | ||
Soleno Therapeutics, Inc. | Common | 834203200 | 9,417 | 4,359,683 | SH | SOLE | 4,359,683 | 0 | 0 | ||
Soleno Therapeutics, Inc. | Warrant | 834203135 | 23 | 188,772 | SH | SOLE | 188,772 | 0 | 0 | ||
Strongbridge Biopharma plc | SHS USD | G85347105 | 4,453 | 918,132 | SH | SOLE | 918,132 | 0 | 0 | ||
Sunesis Pharmaceuticals, Inc. | Common Par | 867328700 | 391 | 195,474 | SH | SOLE | 195,474 | 0 | 0 | ||
Trevena, Inc. | Common | 89532E109 | 3,663 | 1,728,000 | SH | SOLE | 1,728,000 | 0 | 0 | ||
Tricida, Inc. | Common | 89610F101 | 30,297 | 991,711 | SH | SOLE | 991,711 | 0 | 0 | ||
Verona Pharma Plc | ADS | 925050106 | 18,677 | 1,492,951 | SH | SOLE | 1,492,951 | 0 | 0 | ||
Xenon Pharmaceuticals Inc | Common | 98420N105 | 18,552 | 1,405,476 | SH | SOLE | 1,405,476 | 0 | 0 | ||
Zai Lab LTD | ADR | 98887Q104 | 4,500 | 231,010 | SH | SOLE | 231,010 | 0 | 0 | ||
Zogenix, Inc. | Common | 98978L204 | 5,208 | 105,000 | SH | SOLE | 105,000 | 0 | 0 | ||
Zymeworks Inc | Common | 98985W102 | 9,736 | 620,134 | SH | SOLE | 620,134 | 0 | 0 |